

AMENDMENT

In the Claims

Please amend the claims as follows:

- a 1. A method of treating hypertrophy in a subject comprising the step of inhibiting the function of NF-AT3 in a cardiomyocyte, wherein inhibition of NF-AT3 function inhibits hypertrophic gene expression, thereby treating hypertrophy.
- a 2. The method of claim 1, wherein inhibiting the function of NF-AT3 comprises contacting said cardiomyocyte with an agent that binds to and inactivates NF-AT3.

REMARKS

I. Status of the Claims

Claims 1-40 were filed with the application. Claims 2, 3, 5-8 and 10-40 have been withdrawn from consideration. Thus, claim 1, 4 and 9 are under consideration and have been examined. The claims are rejected under 35 U.S.C. §112, first paragraph and second paragraph.

II. Rejections Under 35 U.S.C. §112, Second Paragraph

Claims 1, 4 and 9 stand rejected as vague under the second paragraph of §112. Claims 1, 4 and 9 are said to be indefinite if failing to describe how the function of NF-AT3 is inhibited, and for lacking a step correlating the result with the preamble. Applicants traverse the rejection